Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (328)	10/17/2005 1:14:45 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Vion Gets FDA Fast Track For Anti-Cancer Cloretazine DOW JONES NEWSWIRES October 17, 2005 9:39 a.m. NEW HAVEN, Conn. -- Vion Pharmaceuticals Inc. (VION) said it received fast-track designation from the U.S. Food and Drug Administration for its anti-cancer drug Cloretazine. In a press release Monday, the drug company said the fast-track designation covers Cloretazine for induction treatment of patients over 60 years old with poor-risk acute myelogenous leukemia. In composite Nasdaq SmallCap Market trading, shares of Vion recently rose 9 cents, or 4.8%, to $1.98. Company Web site: vionpharm.com